Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ICPT
- Price
- -
- Stock movement up
- +- (%)
- Company name
- Intercept Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 794.69M
- Ent value
- 1.01B
- Price/Sales
- 2.50
- Price/Book
- 11.06
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 8.88
- PEG
- -
- EPS growth
- -
- 1 year return
- 17.94%
- 3 year return
- -21.50%
- 5 year return
- -29.46%
- 10 year return
- -9.03%
Last updated: 2024-12-17
DIVIDENDS
ICPT does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 2.50 |
| Price to Book | 11.06 |
| EV to Sales | 3.19 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 41.83M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | 2.14 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 102.74M |
| Net receivables | 32.48M |
| Total current assets | 383.44M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 2.15M |
| Total assets | 393.16M |
| Accounts payable | 10.27M |
| Short/Current long term debt | 223.86M |
| Total current liabilities | 90.84M |
| Total liabilities | 321.32M |
| Shareholder's equity | 71.84M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| ICPT | S&P500 | |
| Current price drop from All-time high | -95.89% | -6.07% |
| Highest price drop | -98.02% | -19.00% |
| Date of highest drop | 24 May 2023 | 8 Apr 2025 |
| Avg drop from high | -70.76% | -2.76% |
| Avg time to new high | 70 days | 5 days |
| Max time to new high | 2436 days | 89 days |
COMPANY DETAILS
Marketcap
794.69M
Marketcap category
Small-cap
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..
Employees
341
Investor relations
-
SEC filings
CEO
Mark E. Pruzanski
Country
USA
City
New York
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner